Showing results (31-40 of 51) with videos related to
Sort By:
Pageof 6
Melanoma Research|September 15, 2018
Postsurgical treatment landscape and economic burden of locoregional and distant recurrence in patients with operable nonmetastatic melanomaAhmad Tarhini, Sameer R Ghate, Raluca Ionescu-Ittu, et al.Immunotherapy|September 4, 2018
Sequential treatment approaches in the management of BRAF wild-type advanced melanoma: a cost-effectiveness analysisAhmad Tarhini, Agnes Benedict, David McDermott, et al.Journal of Clinical Medicine|February 9, 2021
Early Cortisol and Inflammatory Responses to Parental Cancer and Their Impact on Functional Impairment in YouthBenjamin Hayes, Jacob Brent, Yongqi Zhong, et al.The American Journal of Dermatopathology|October 12, 2018
Decreased T-Cell Programmed Death Receptor-1 Expression in Pregnancy-Associated MelanomaJennifer S Ko, Brian R Gastman, Ruzica Conic, et al.Obesity Surgery|January 17, 2022
One-Anastomosis Gastric Bypass Revision for Gastroesophageal Reflux Disease: Long Versus Short Biliopancreatic Limb Roux-en-Y Gastric BypassAhmad Tarhini, Claire Rives-Lange, Anne-Sophie Jannot, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2008
Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemiaKenneth A Foon, Michael Boyiadzis, Stephanie R Land, et al.Research Square|March 30, 2023
DRPPM-PATH-SURVEIOR: Plug-and-Play Survival Analysis of Pathway-level Signatures and Immune ComponentsAlyssa Obermayer, Darwin Chang, Gabrielle Nobles, et al.Journal for Immunotherapy of Cancer|October 25, 2018
Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoireAhmad Tarhini, Yan Lin, Huang Lin, et al.Investigational New Drugs|November 12, 2017
A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanomaSandra P D'Angelo, Omid A Hamid, Ahmad Tarhini, et al.BMC Bioinformatics|June 28, 2023
PATH-SURVEYOR: pathway level survival enquiry for immuno-oncology and drug repurposingAlyssa N Obermayer, Darwin Chang, Gabrielle Nobles, et al.Pageof 6